CN100417417C - Surface-modified hydrophobically modified drug-carried chitosan polymer micelle and method for preparing same - Google Patents
Surface-modified hydrophobically modified drug-carried chitosan polymer micelle and method for preparing same Download PDFInfo
- Publication number
- CN100417417C CN100417417C CNB2006100516010A CN200610051601A CN100417417C CN 100417417 C CN100417417 C CN 100417417C CN B2006100516010 A CNB2006100516010 A CN B2006100516010A CN 200610051601 A CN200610051601 A CN 200610051601A CN 100417417 C CN100417417 C CN 100417417C
- Authority
- CN
- China
- Prior art keywords
- micelle
- oligochitosan
- modified
- medicine carrying
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The present invention provides a medicine carrying micelle modified by a hydrophobic modified chitosan oligosaccharide polymer on the surface. The micelle is prepared by grafting chitosan with the average molecular weight of 1.5kD to 51kD with fatty acid of C10 to C22. In the present invention, bifunctional organic small molecules are used for modifying the surface of amido or hydroxyl on chitosan oligosaccharide molecules on the surface of a polymer on the basis of the micelle of a hydrophobic modified chitosan oligosaccharide polymer; the instability of the diluted polymer micelle is improved by bridging chemical bonds among molecules on the surface of the polymer micelle; meanwhile, the original loose structure of the surface of the polymer micelle is changed into a dense net-shaped structure by bridging chemical bonds among molecules on the surface of the polymer micelle so as to reduce the unique sudden medicine release of the polymer micelle and achieve the purpose of the slow medicine release control. The present invention has the advantage of reasonable design, and the provided medicine carrying micelle is a nanometer carrier with good organelle target and can be used in the fields of life science and pharmacy.
Description
Technical field
The invention belongs to the finishing of polymeric micellar, relate to of the finishing of bi-functional organic molecule to the hydrophobic modified chitin polymer micelle, and, reach the slow controlled release properties of polymer drug-carried micelle by control to the finishing degree of polymeric micellar.
Background technology
(polymeric micelles is the novel nano-carrier of a class that was developing in recent years PMs) to polymeric micellar, has solubilising, targeting, low toxicity and macrocyclic advantage.It is by amphipathic polymer spontaneous formation in aqueous environments, has unique nuclear-film (shell) structure.Endorsing of its inside to insoluble drug, polypeptide and protein medicaments and gene provide bank, the hydrophilic adventitia then can carry out physicochemical property to be modified, reach that targeting distributes in the body, escape mononuclear phagocyte engulf, improve effect such as biomembrane transhipment.Polymeric micellar self can gather tumor tissues by " enhanced seeing through and retention effect " (enhanced permeability andretention effect).
Polymeric micellar is when the concentration of amphipathic polymer in solution is higher than its critical aggregate concentration, the nanometer micelle with dynamic equilibrium feature of spontaneous formation.Discover that at body the polymeric drug delivery micelle exists the problem of stability after the body fluid dilution; And improve the concentration of polymer, can cause the high toxicity of carrier self.Polymeric micellar is formed by the intersegmental hydrophobic interaction power of the hydrophobic chain of amphipathic nature polyalcohol simultaneously, polymeric micellar also is because the result of the intersegmental hydrophobic interaction power of the hydrophobic chain of medicine and amphipathic nature polyalcohol to the solubilising of lipophilic drugs, therefore hydrophobic interaction power belongs to a kind of physical force (Van der Waals force), and the drug release ubiquity of polymer drug-carried micelle prominent releasing and drug release problem fast.Though polymeric micellar can have targeting and macrocyclic function, the prominent of it released and medicine rapid release feature, lowered the targeting of polymeric micellar Chinese medicine to tissue, cell and organelle greatly.Therefore the clinical practice of polymer drug-carried micelle still is blank.
Chitosan is the cationic polymer that a class is made up of glucosamine, has good biocompatibility, hypotoxicity and biodegradable.Chitosan is widely used in excipient substance, hemostatic material, tissue engineering bracket etc.Under the physiological pH condition (7.2-7.4) is water insoluble for the macromolecule chitosan, and the low-molecular weight chitoglycan (oligochitosan by enzymatic degradation, Chitosan oligosaccharide, CSO) has good water-solubility, oligochitosan is after long-chain fatty acid grafting modification, can the spontaneous polymeric micellar that in aqueous solution, forms 5～1000nm, and have the nucleus transport function.This polymeric micellar has been applied to the carrier of lipotropy and biopharmaceutical macromolecular drugs such as protein, DNA.
Summary of the invention
First purpose of the present invention provides surface-modified hydrophobically modified drug-carried chitosan polymer micelle, the consisting of of micelle: the chitosan of mean molecule quantity 1.5kD～51kD and C
10～C
22The fatty acid grafting obtain, the amino group substitution degree of chitosan is 1%～50% in the grafting, critical micelle concentration is 0.01～0.1mg/ml.The present invention is on the basis of hydrophobic modified chitin polymer micelle, with the bi-functional organic molecule amino on the polymer surfaces oligochitosan molecule or hydroxyl are carried out surface chemical modification, by the chemical bond between the polymeric micellar surface molecular is built bridge, improve the unstability of polymeric micellar after dilution; By the chemical bond between the polymeric micellar surface molecular is built bridge, change the original loose structure in polymeric micellar surface simultaneously, form comparatively fine and close network structure, reduce that the distinctive medicine of polymeric micellar is prominent to be released, and reach slow controlled release purpose medicine.Medicine as surface-modified hydrophobically modified oligochitosan medicine carrying micelle is a lipophilic drugs, as paclitaxel etc.
Second purpose of the present invention provides the preparation method of surface-modified hydrophobically modified oligochitosan medicine carrying micelle, realizes by following scheme:
(1) oligochitosan preparation: getting commercially available molecular weight is the high-molecular weight chitosan (90～95% deacetylation) of 450kDa, stirring and dissolving under 55～60 ℃ and pH5.0 condition, add cellulose degraded in cellulase and chitosan ratio 0.5: 100 (w/w), remove by filter impurity.According to instructions for use, respectively from the ultrafilter membrane of 1kDa, 10kDa, 50kDa, 100kDa, 200kDa, select suitable ultrafiltration molecular weight membrane ultrafiltration classification, the ultrafiltrate lyophilization, molecular weight (preferred oligochitosan is 1～50kDa), deacetylation is greater than 80% low-molecular-weight oligochitosan, gel permeation chromatography molecular weight less than 200kDa.
(2) hydrophobic modified chitin preparation: get above-mentioned oligochitosan aqueous solution,, control 50 ℃～90 ℃, reacted 5～48 hours according to oligochitosan, fatty acid, crosslinked coupling agent carbodiimide mol ratio 1: 1～50: 1～50.End reaction liquid dialysis purification, lyophilization obtains hydrophobic modified chitin; Fatty acid is selected from, in capric acid myristic acid, palmitic acid, oleic acid, stearic acid, behenic acid etc. any.
(3) carry the preparation of lipophilic drugs hydrophobic modified chitin micelle: get hydrophobic modified chitin, it is an amount of to add distilled water, the water-bath ultra-sonic dispersion, get micelle solution, get micelle solution, add lipophilic drugs or its solution, it is ultrasonic to pop one's head in, and gets hydrophobic modified chitin medicine carrying micelle.
(4) finishing of medicine carrying micelle: get the medicine carrying micelle solution, add quantitatively (mol ratio 1: 1～100 of control hydrophobic modified chitin and bi-functional organic molecule) bi-functional organic molecule, solution room temperature lower magnetic force stirs certain hour, gets surface-modified hydrophobically modified oligochitosan medicine carrying micelle.
Described bi-functional organic molecule comprises the difunctional organic molecule coating material that can react with the amino on the oligochitosan: glutaraldehyde, genipin, binary fatty acid, diglycidyl ether of ethylene glycol etc.; And the difunctional organic molecule coating material that can react: isophorone-vulcabond with the hydroxyl on the oligochitosan.
The structural formula of described glutaraldehyde is:
The structural formula of described genipin is:
The structural formula of described diglycidyl ether of ethylene glycol is:
Described binary fatty acid: the structural formula as the Laurel diacid is:
The structural formula of described isophorone-vulcabond is:
The material of the used surface-modified hydrophobically modified oligochitosan medicine carrying micelle of the present invention is a disclosed micelle material in number of patent application 200510050798.1 and 200610050516.2.Consisting of of micelle: the chitosan of mean molecule quantity 1.5kD～51kD and C
10～C
22The fatty acid grafting obtain, the amino group substitution degree of chitosan is 1%～50% in the grafting, critical micelle concentration is 0.01～0.1mg/ml.Realize by following scheme:
(1) oligochitosan preparation: getting commercially available molecular weight is the high-molecular weight chitosan (90～95% deacetylation) of 450kDa, stirring and dissolving under 55～60 ℃ and pH5.0 condition, add cellulose degraded in cellulase and chitosan ratio 0.5: 100 (w/w), remove by filter impurity.According to instructions for use, respectively from the ultrafilter membrane of molecular weight 1kDa, 10kDa, 50kDa, 100kDa, 200kDa, select suitable ultrafilter membrane ultrafiltration classification, the ultrafiltrate lyophilization, molecular weight (preferred oligochitosan is 1～50kDa), deacetylation is greater than 80% low-molecular-weight oligochitosan, gel permeation chromatography molecular weight less than 200kDa.
(2) hydrophobic modified chitin preparation: get above-mentioned oligochitosan aqueous solution,, control 50 ℃～90 ℃, reacted 5～48 hours according to oligochitosan, fatty acid, crosslinked coupling agent carbodiimide mol ratio 1: 1～50: 1～50.End reaction liquid dialysis purification, lyophilization obtains hydrophobic modified chitin; Fatty acid is selected from, in capric acid myristic acid, palmitic acid, oleic acid, stearic acid, behenic acid etc. any.
(3) carry the preparation of lipophilic drugs hydrophobic modified chitin micelle: get hydrophobic modified chitin, it is an amount of to add distilled water, the water-bath ultra-sonic dispersion, micelle solution.
Usefulness of the present invention is:
(1) the functional organic molecule that provides is modified hydrophobic modified chitin medicine carrying micelle, is a kind of nano-carrier with good organelle targeting, can be applicable to life science and pharmaceutical field.Utilize this carrier, can be used for the targeted therapy of medicine, improve the curative effect of medicine.
(2) among the present invention, the micelle surface modification technology of employing by the chemical bond between the polymeric micellar surface molecular is built bridge, is improved the unstability of polymeric micellar after dilution; By the chemical bond between the polymeric micellar surface molecular is built bridge, change the original loose structure in polymeric micellar surface simultaneously, form comparatively fine and close network structure, can reduce that the distinctive medicine of polymeric micellar is prominent to be released, and reach slow controlled release purpose.
(3) bi-functional organic molecule provided by the invention is modified the preparation method of hydrophobic modified chitin medicine carrying micelle, and method is simple.Selected main raw material(s) is an oligochitosan, comes from the nature Crustacean, has low toxicity, biodegradable characteristic.
Description of drawings
Fig. 1 is the release in vitro curve that carries paclitaxel hydrophobic modified chitin micelle of different surfaces degree of modification.
Fig. 2 is the release in vitro curve that carries paclitaxel hydrophobic modified chitin micelle of different surfaces degree of modification.
Fig. 3 is the release in vitro curve that carries paclitaxel hydrophobic modified chitin micelle of different surfaces degree of modification.
Fig. 4 is the release in vitro curve that carries paclitaxel hydrophobic modified chitin micelle of different surfaces degree of modification.
The specific embodiment
The present invention is further described with accompanying drawing in conjunction with the embodiments.
Embodiment one
1, the preparation of oligochitosan
Chitosan (mean molecule quantity 450kDa) 6g adds in the aqueous hydrochloric acid solution of 200mL 1.25% (v/v), stirring and dissolving under 55～60 ℃ of conditions, transfer pH to 5.0 with weak ammonia or dilute hydrochloric acid, add cellulase in cellulase and chitosan ratio 0.5: 100 (w/w), after the controlling reaction time 8 hours, with product 4000r * min
-1Centrifugal 10 minutes, supernatant was with 0.45 μ m microporous filter membrane pretreatment, and with the ultrafilter membrane ultrafiltration classification of different molecular weight, the ultrafiltrate lyophilization obtains the oligochitosan of certain molecular weight.And be 50.6kDa by the gel permeation chromatography mean molecule quantity.
2, the preparation of hydrophobic modified chitin
Get above-mentioned oligochitosan 5.0g, the accurate title, decide.After adding 40ml distilled water stirring and dissolving, add carbodiimide 30mg, stirring and dissolving.With the stearic acid of 0.35g, add in the 10ml methanol solution, behind the ultrasonic dissolution, add in the above-mentioned oligochitosan solution, at 400rmin
-1Under the magnetic agitation condition, 60 ℃ of control temperature are more than the response time 24h.End reaction liquid is put bag filter, and distilled water dialysis 24h removes byproduct of reaction.The dialysis solution lyophilization prepares hydrophobic modified chitin.
The amino group substitution degree of oligochitosan behind the hydrophobically modified adopts the trinitro-benzene-sulfonic acid method to measure.(0.5～9mg), the accurate title, decide, and is dissolved in respectively in the redistilled water of 2ml, adds the trinitro-benzene-sulfonic acid 2ml of the sodium bicarbonate solution 2ml and 0.1% (w/v) of 4% (w/v), hatches 2h for 37 ℃ to get not commensurability oligochitosan.Add 2N hydrochloric acid 2ml, shake up, measure absorption value, preparation standard curve at 344nm wavelength place.Get above-mentioned oligochitosan 4mg and be dissolved in the 2ml redistilled water, with the method operation, measure the absorption value at 344nm wavelength place, calculating its substitution value by standard curve is 5%.
3, hydrophobic modified chitin medicine carrying micelle preparation
Get hydrophobic modified chitin 10mg, the accurate title, decide.Add the ultrasonic 10min of an amount of distilled water water-bath and disperse, be settled to 100ml, get the hydrophobic modified chitin micelle solution.
Zetasizer 3000HS analysis-e/or determining particle diameter and surface potential.The mean diameter of hydrophobic modified chitin micelle is 74.6nm; Surface potential is 53.2 ± 0.1mV.
Get micelle solution 5ml, add the paclitaxel standard methanol solution (concentration 1mg/ml) of quantitative volume.After decompress filter was removed methanol, ultrasonic 50 times of probe (400W, work 2s stops 3s) got the medicine carrying micelle under condition of ice bath.
Zetasizer 3000HS analysis-e/or determining particle diameter and surface potential.The mean diameter of hydrophobic modified chitin medicine carrying micelle is 175.1nm; Surface potential is 58.7 ± 0.1mV.The envelop rate of medicine is 94.82%.
4. the finishing of medicine carrying micelle: get medicine carrying micelle solution 5ml, add quantitative glutaraldehyde, the mol ratio that makes polymer and glutaraldehyde is 1: 10 and 1: 20, and magnetic agitation is 4 hours at normal temperatures, and the medicine carrying micelle is carried out finishing.
Zetasizer 3000HS analysis-e/or determining particle diameter and surface potential.The mol ratio of using polymer and glutaraldehyde is that the mean diameter of 1: 10 surface-modified hydrophobically modified oligochitosan medicine carrying micelle is 131.6nm; Surface potential is 55.6 ± 0.1mV; The envelop rate of medicine is 97.49%.The mol ratio of using polymer and glutaraldehyde is that the mean diameter of 1: 20 surface-modified hydrophobically modified oligochitosan medicine carrying micelle is 112.6nm; Surface potential is 44.6 ± 0.1mV; The envelop rate of medicine is 97.27%.
5. the release in vitro of medicine carrying micelle: get medicine carrying micelle or finishing medicine carrying micelle solution 2ml, be enclosed within the bag filter (molecular weight 7000), place 2M sodium salicylate PBS (7.4) release medium of 30ml to carry out release in vitro, timing sampling, sample are crossed 0.22 μ m microporous filter membrane, and HPLC measures filtrate drug level (chromatographic column: C18 post, mobile phase: acetonitrile: water=50: 50, detect wavelength: 227nm, sample size: 20 μ l, flow velocity: 1ml/min.)。Add or change release medium after the sampling, keep the release medium constant volume.Its result is referring to Fig. 1.The result shows, along with the increase of the finishing degree of polymeric micellar, release rate of drugs is obviously slowed down.
Embodiment two
1, the preparation of oligochitosan
Chitosan (mean molecule quantity 450kDa) 6g adds in the aqueous hydrochloric acid solution of 200mL 1.25% (v/v), stirring and dissolving under 55～60 ℃ of conditions, transfer pH to 5.0 with weak ammonia or dilute hydrochloric acid, add cellulase in cellulase and chitosan ratio 0.5: 100 (w/w), after the controlling reaction time 8 hours, with product 4000r * min
-1Centrifugal 10 minutes, supernatant was with 0.45 μ m microporous filter membrane pretreatment, and with the ultrafilter membrane ultrafiltration classification of different molecular weight, the ultrafiltrate lyophilization obtains the oligochitosan of certain molecular weight.And be 50.6kDa by the gel permeation chromatography mean molecule quantity.
2, the preparation of hydrophobic modified chitin
Get above-mentioned oligochitosan 5.0g, the accurate title, decide.After adding 40ml distilled water stirring and dissolving, add carbodiimide 120mg, stirring and dissolving.With the stearic acid of 1.4g, add in the 10ml methanol solution, behind the ultrasonic dissolution, add in the above-mentioned oligochitosan solution, at 400rmin
-1Under the magnetic agitation condition, 60 ℃ of control temperature are more than the response time 24h.End reaction liquid is put bag filter, and distilled water dialysis 24h removes byproduct of reaction.The dialysis solution lyophilization prepares hydrophobic modified chitin.
The amino group substitution degree of oligochitosan behind the hydrophobically modified adopts the trinitro-benzene-sulfonic acid method to measure.(0.5～9mg), the accurate title, decide, and is dissolved in respectively in the redistilled water of 2ml, adds the trinitro-benzene-sulfonic acid 2ml of the sodium bicarbonate solution 2ml and 0.1% (w/v) of 4% (w/v), hatches 2h for 37 ℃ to get not commensurability oligochitosan.Add 2N hydrochloric acid 2ml, shake up, measure absorption value, preparation standard curve at 344nm wavelength place.Get above-mentioned oligochitosan 4mg and be dissolved in the 2ml redistilled water, with the method operation, measure the absorption value at 344nm wavelength place, calculating its substitution value by standard curve is 12%.
3, hydrophobic modified chitin medicine carrying micelle preparation
Get hydrophobic modified chitin 10mg, the accurate title, decide.Add the ultrasonic 10min of an amount of distilled water water-bath and disperse, be settled to 100ml, get the hydrophobic modified chitin micelle solution.
Zetasizer 3000HS analysis-e/or determining particle diameter and surface potential.The mean diameter of hydrophobic modified chitin micelle is 67.7nm; Surface potential is 52.1 ± 0.1mV.
Get micelle solution 5ml, add the paclitaxel standard methanol solution (concentration 1mg/ml) of quantitative volume.After decompress filter was removed methanol, ultrasonic 50 times of probe (400W, work 2s stops 3s) got the medicine carrying micelle under condition of ice bath.
Zetasizer 3000HS analysis-e/or determining particle diameter and surface potential.The mean diameter of hydrophobic modified chitin medicine carrying micelle is 117.8nm; Surface potential is 56.8 ± 0.1mV.The envelop rate of medicine is 97.11%.
4. the finishing of medicine carrying micelle: get medicine carrying micelle solution 5ml, the quantitative glutaraldehyde of middle adding, the mol ratio that makes polymer and glutaraldehyde is 1: 10 and 1: 20, magnetic agitation is 4 hours at normal temperatures, and the medicine carrying micelle is carried out finishing.
Zetasizer 3000HS analysis-e/or determining particle diameter and surface potential.The mol ratio of using polymer and glutaraldehyde is that the mean diameter of 1: 10 surface-modified hydrophobically modified oligochitosan medicine carrying micelle is 126.5nm; Surface potential is 56.8 ± 0.1mV; The envelop rate of medicine is 96.8%.The mol ratio of using polymer and glutaraldehyde is that the mean diameter of 1: 20 surface-modified hydrophobically modified oligochitosan medicine carrying micelle is 77.7nm; Surface potential is 46.7 ± 0.1mV; The envelop rate of medicine is 97%.
5. the release in vitro of medicine carrying micelle: get medicine carrying micelle or finishing medicine carrying micelle solution 2ml, be enclosed within the bag filter (molecular weight 7000), place 2M sodium salicylate PBS (7.4) release medium of 30ml to carry out release in vitro, timing sampling, sample is crossed 0.22 μ m microporous filter membrane, and HPLC measures the filtrate drug level.Add or change release medium after the sampling, keep the release medium constant volume.Its result is referring to Fig. 2.The result shows equally, and along with the increase of the finishing degree of polymeric micellar, release rate of drugs is obviously slowed down.
Embodiment three
1, the preparation of oligochitosan
Chitosan (mean molecule quantity 450kDa) 6g adds in the aqueous hydrochloric acid solution of 200mL1.25% (v/v), stirring and dissolving under 55～60 ℃ of conditions, transfer pH to 5.0 with weak ammonia or dilute hydrochloric acid, add cellulase in cellulase and chitosan ratio 0.5: 100 (w/w), after the controlling reaction time 8 hours, with product 4000r * min
-1Centrifugal 10 minutes, supernatant was with 0.45 μ m microporous filter membrane pretreatment, and with the ultrafilter membrane ultrafiltration classification of different molecular weight, the ultrafiltrate lyophilization obtains the oligochitosan of certain molecular weight.And be 50.6kDa by the gel permeation chromatography mean molecule quantity.
2, the preparation of hydrophobic modified chitin
Get above-mentioned oligochitosan 5.0g, the accurate title, decide.After adding 40ml distilled water stirring and dissolving, add carbodiimide 300mg, stirring and dissolving.With the stearic acid of 3.5g, add in the 10ml methanol solution, behind the ultrasonic dissolution, add in the above-mentioned oligochitosan solution, at 400rmin
-1Under the magnetic agitation condition, 60 ℃ of control temperature are more than the response time 24h.End reaction liquid is put bag filter, and distilled water dialysis 24h removes byproduct of reaction.The dialysis solution lyophilization prepares hydrophobic modified chitin.
The amino group substitution degree of oligochitosan behind the hydrophobically modified adopts the trinitro-benzene-sulfonic acid method to measure.(0.5～9mg), the accurate title, decide, and is dissolved in respectively in the redistilled water of 2ml, adds the trinitro-benzene-sulfonic acid 2ml of the sodium bicarbonate solution 2ml and 0.1% (w/v) of 4% (w/v), hatches 2h for 37 ℃ to get not commensurability oligochitosan.Add 2N hydrochloric acid 2ml, shake up, measure absorption value, preparation standard curve at 344nm wavelength place.Get above-mentioned oligochitosan 4mg and be dissolved in the 2ml redistilled water, with the method operation, measure the absorption value at 344nm wavelength place, calculating its substitution value by standard curve is 40%.
3, hydrophobic modified chitin medicine carrying micelle preparation
Get hydrophobic modified chitin 10mg, the accurate title, decide.Add the ultrasonic 10min of an amount of distilled water water-bath and disperse, be settled to 100ml, get the hydrophobic modified chitin micelle solution.
Zetasizer 3000HS analysis-e/or determining particle diameter and surface potential.The mean diameter of hydrophobic modified chitin micelle is 31.4nm; Surface potential is 39.0 ± 0.1mV.
Get micelle solution 5ml, add the paclitaxel standard methanol solution (concentration 1mg/ml) of quantitative volume.After decompress filter was removed methanol, ultrasonic 50 times of probe (400W, work 2s stops 3s) got the medicine carrying micelle under condition of ice bath.
Zetasizer 3000HS analysis-e/or determining particle diameter and surface potential.The mean diameter of hydrophobic modified chitin medicine carrying micelle is 57.3nm; Surface potential is 53.2 ± 0.1mV.The envelop rate of medicine is 97.04%.4. the finishing of medicine carrying micelle: get medicine carrying micelle solution 5ml, the quantitative glutaraldehyde of middle adding, the mol ratio that makes polymer and glutaraldehyde is 1: 1 and 1: 100, magnetic agitation is 4 hours at normal temperatures, and the medicine carrying micelle is carried out finishing.Different curing ratios sees Table 1 to the influence of particle diameter, current potential and the entrapment efficiency of formed curing medicine carrying micelle.
Table 1. curing ratio is to the influence of particle diameter, current potential and the entrapment efficiency of curing medicine carrying micelle
Zetasizer 3000HS analysis-e/or determining particle diameter and surface potential.The mol ratio of using polymer and glutaraldehyde is that the mean diameter of 1: 1 surface-modified hydrophobically modified oligochitosan medicine carrying micelle is 35.7nm; Surface potential is 38.0 ± 0.1mV.The envelop rate of medicine is 97.83%.The mol ratio of using polymer and glutaraldehyde is that the mean diameter of 1: 10 surface-modified hydrophobically modified oligochitosan medicine carrying micelle is 67.2nm; Surface potential is 49.8 ± 0.1mV; The envelop rate of medicine is 98.77%.The mol ratio of using polymer and glutaraldehyde is that the mean diameter of 1: 20 surface-modified hydrophobically modified oligochitosan medicine carrying micelle is 35.8nm; Surface potential is 44.0 ± 0.1mV; The envelop rate of medicine is 99.14%.The mol ratio of using polymer and glutaraldehyde is that the mean diameter of 1: 100 surface-modified hydrophobically modified oligochitosan medicine carrying micelle is 27.5nm; Surface potential is 18.0 ± 0.1mV; The envelop rate of medicine is 99.36%.
5. the release in vitro of medicine carrying micelle: get medicine carrying micelle or finishing medicine carrying micelle solution 2ml, be enclosed within the bag filter (molecular weight 7000), place 2M sodium salicylate PBS (7.4) release medium of 30ml to carry out release in vitro, timing sampling, sample is crossed 0.22 μ m microporous filter membrane, and HPLC measures the filtrate drug level.Add or change release medium after the sampling, keep the release medium constant volume.Its result is referring to Fig. 3.The result shows equally, and along with the increase of the finishing degree of polymeric micellar, release rate of drugs is obviously slowed down.
Embodiment four
1, the preparation of oligochitosan
Chitosan (mean molecule quantity 450kDa) 6g adds in the aqueous hydrochloric acid solution of 200mL 1.25% (v/v), stirring and dissolving under 55～60 ℃ of conditions, transfer pH to 5.0 with weak ammonia or dilute hydrochloric acid, add cellulase in cellulase and chitosan ratio 0.5: 100 (w/w), after the controlling reaction time 8 hours, with product 4000r * min
-1Centrifugal 10 minutes, supernatant was with 0.45 μ m microporous filter membrane pretreatment, and with the ultrafilter membrane ultrafiltration classification of different molecular weight, the ultrafiltrate lyophilization obtains the oligochitosan of certain molecular weight.And be 50.6kDa by the gel permeation chromatography mean molecule quantity.
2, the preparation of hydrophobic modified chitin
Get above-mentioned oligochitosan 5.0g, the accurate title, decide.After adding 40ml distilled water stirring and dissolving, add carbodiimide 300mg, stirring and dissolving.With the stearic acid of 3.5g, add in the 10ml methanol solution, behind the ultrasonic dissolution, add in the above-mentioned oligochitosan solution, at 400rmin
-1Under the magnetic agitation condition, 60 ℃ of control temperature are more than the response time 24h.End reaction liquid is put bag filter, and distilled water dialysis 24h removes byproduct of reaction.The dialysis solution lyophilization prepares hydrophobic modified chitin.
The amino group substitution degree of oligochitosan behind the hydrophobically modified adopts the trinitro-benzene-sulfonic acid method to measure.(0.5～9mg), the accurate title, decide, and is dissolved in respectively in the redistilled water of 2ml, adds the trinitro-benzene-sulfonic acid 2ml of the sodium bicarbonate solution 2ml and 0.1% (w/v) of 4% (w/v), hatches 2h for 37 ℃ to get not commensurability oligochitosan.Add 2N hydrochloric acid 2ml, shake up, measure absorption value, preparation standard curve at 344nm wavelength place.Get above-mentioned oligochitosan 4mg and be dissolved in the 2ml redistilled water, with the method operation, measure the absorption value at 344nm wavelength place, calculating its substitution value by standard curve is 40%.
3, hydrophobic modified chitin medicine carrying micelle preparation
Get hydrophobic modified chitin 10mg, the accurate title, decide.Add the ultrasonic 10min of an amount of distilled water water-bath and disperse, be settled to 100ml, get the hydrophobic modified chitin micelle solution.
Zetasizer 3000HS analysis-e/or determining particle diameter and surface potential.The mean diameter of hydrophobic modified chitin micelle is 31.4nm; Surface potential is 39.0 ± 0.1mV.
Get micelle solution 5ml, add the paclitaxel standard methanol solution (concentration 1mg/ml) of quantitative volume.After decompress filter was removed methanol, ultrasonic 50 times of probe (400W, work 2s stops 3s) got the medicine carrying micelle under condition of ice bath.
Zetasizer 3000HS analysis-e/or determining particle diameter and surface potential.The mean diameter of hydrophobic modified chitin medicine carrying micelle is 57.3nm; Surface potential is 53.2 ± 0.1mV.The envelop rate of medicine is 97.04%.
4. the finishing of medicine carrying micelle: get medicine carrying micelle solution 5ml, quantitative isophorone-the vulcabond of middle adding, the mol ratio that makes polymer and isophorone-vulcabond is 1: 10 and 1: 20, and magnetic agitation is 4 hours at normal temperatures, and the medicine carrying micelle is carried out finishing.
Zetasizer 3000HS analysis-e/or determining particle diameter and surface potential.The mol ratio of using polymer and isophorone-vulcabond is that the mean diameter of 1: 10 surface-modified hydrophobically modified oligochitosan medicine carrying micelle is 53.4nm; Surface potential is 34.7 ± 0.1mV; The envelop rate of medicine is 96.75%.The mol ratio of using polymer and isophorone-vulcabond is that the mean diameter of 1: 20 surface-modified hydrophobically modified oligochitosan medicine carrying micelle is 43.1nm; Surface potential is 35.2 ± 0.1mV; The envelop rate of medicine is 98.34%.
5. the release in vitro of medicine carrying micelle: get medicine carrying micelle or finishing medicine carrying micelle solution 2ml, be enclosed within the bag filter (molecular weight 7000), place 2M sodium salicylate PBS (7.4) release medium of 30ml to carry out release in vitro, timing sampling, sample is crossed 0.22 μ m microporous filter membrane, and HPLC measures the filtrate drug level.Add or change release medium after the sampling, keep the release medium constant volume.Its result is referring to Fig. 4.The result shows equally, and along with the increase of the finishing degree of polymeric micellar, release rate of drugs is obviously slowed down.
Embodiment five
1, oligochitosan, hydrophobic modified chitin, hydrophobic modified chitin medicine carrying micelle prepare identical with embodiment one～four.
2, the finishing of medicine carrying micelle: get medicine carrying micelle solution 5ml, the genipin alcoholic solution of middle adding 1ml, the mol ratio that makes polymer and genipin is 1: 20, magnetic agitation is 4 hours at normal temperatures, and the medicine carrying micelle is carried out finishing.
Zetasizer 3000HS analysis-e/or determining particle diameter and surface potential.The mean diameter of surface-modified hydrophobically modified oligochitosan medicine carrying micelle is 41.8nm; Surface potential is 43.2 ± 0.1mV; The envelop rate of medicine is 98.15%.
Embodiment six
1, oligochitosan, hydrophobic modified chitin, hydrophobic modified chitin medicine carrying micelle prepare identical with embodiment one～four.
2, the finishing of medicine carrying micelle: get medicine carrying micelle solution 5ml, the alcoholic solution of middle adding 1ml Laurel diacid, the mol ratio that makes polymer and Laurel diacid is 1: 20, magnetic agitation is 4 hours at normal temperatures, and the medicine carrying micelle is carried out finishing.
Zetasizer 3000HS analysis-e/or determining particle diameter and surface potential.The mean diameter of surface-modified hydrophobically modified oligochitosan medicine carrying micelle is 37.6nm; Surface potential is 45.2 ± 0.1mV; The envelop rate of medicine is 98.97%.
Embodiment seven
1, oligochitosan, hydrophobic modified chitin, hydrophobic modified chitin medicine carrying micelle prepare identical with embodiment one～four.
2, the finishing of medicine carrying micelle: get medicine carrying micelle solution 5ml, the middle alcoholic solution that adds the 1ml diglycidyl ether of ethylene glycol, the mol ratio that makes polymer and diglycidyl ether of ethylene glycol is 1: 20, and magnetic agitation is 4 hours at normal temperatures, and the medicine carrying micelle is carried out finishing.
Zetasizer 3000HS analysis-e/or determining particle diameter and surface potential.The mean diameter of surface-modified hydrophobically modified oligochitosan medicine carrying micelle is 45.3nm; Surface potential is 34.5 ± 0.1mV; The envelop rate of medicine is 99.23%.
Embodiment eight
1, oligochitosan, hydrophobic modified chitin, hydrophobic modified chitin medicine carrying micelle prepare identical with embodiment one～four.
2, the finishing of medicine carrying micelle: get medicine carrying micelle solution 5ml, the middle alcoholic solution that adds 1ml isophorone-vulcabond, the mol ratio that makes polymer and isophorone-vulcabond is 1: 20, and magnetic agitation is 4 hours at normal temperatures, and the medicine carrying micelle is carried out finishing.
Zetasizer 3000HS analysis-e/or determining particle diameter and surface potential.The mean diameter of surface-modified hydrophobically modified oligochitosan medicine carrying micelle is 56.4nm; Surface potential is 31.4 ± 0.1mV; The envelop rate of medicine is 98.67%.
Need not further to elaborate, believe and adopt the disclosed content in front, those skilled in the art can use the present invention to greatest extent.Therefore, the preferred specific embodiments of front is interpreted as only illustrating, but not limits the scope of the invention by any way.
Claims (5)
1. surface-modified hydrophobically modified oligochitosan medicine carrying micelle, the consisting of of micelle: the oligochitosan of mean molecule quantity 1.5kD～51kD and C
10～C
22The grafting of fatty acid, the amino group substitution degree of oligochitosan is 1%～50% in the grafting, critical micelle concentration is 0.01～0.1mg/ml, it is characterized in that: amino on the polymer surfaces oligochitosan molecule or hydroxyl are carried out chemical modification with the bi-functional organic molecule, wherein said bi-functional organic molecule is selected glutaraldehyde for use, genipin, the binary fatty acid, diglycidyl ether of ethylene glycol, in isophorone-vulcabond any, described chemical modification is to get the medicine carrying micelle solution, add bi-functional organic molecule solution, the mol ratio of control hydrophobic modified chitin and bi-functional organic molecule is that 1: 1～100,15～50 ℃ lower magnetic forces stirred 2～24 hours.
2. surface-modified hydrophobically modified oligochitosan medicine carrying micelle according to claim 1 is characterized in that: the medicine as surface-modified hydrophobically modified oligochitosan medicine carrying micelle is a lipophilic drugs.
3. surface-modified hydrophobically modified oligochitosan medicine carrying micelle according to claim 2 is characterized in that: as the choice of drug paclitaxel of surface-modified hydrophobically modified oligochitosan medicine carrying micelle.
4. the preparation method of the arbitrary described surface-modified hydrophobically modified oligochitosan medicine carrying micelle of claim 1-3, (1) getting molecular weight is 450kDa, the high-molecular weight chitosan of 90～95% deacetylations, 90～95% deacetylations, stirring and dissolving under 55～60 ℃ and pH5.0 condition, by cellulase and chitosan weight ratio is 0.5: 100 adding cellulose degraded, remove by filter impurity, with ultrafilter membrane ultrafiltration classification, the filtrate lyophilization, get the low-molecular-weight oligochitosan of molecular weight less than 200kDa, get above-mentioned oligochitosan aqueous solution, according to oligochitosan, fatty acid, crosslinked coupling agent carbodiimide mol ratio 1: 1～50: 1～50 is controlled 50 ℃～90 ℃, reacts 5～48 hours, end reaction liquid dialysis purification, lyophilization obtains hydrophobic modified chitin; It is characterized in that further comprising the steps of:
(2) get hydrophobic modified chitin, the adding distilled water is an amount of, the water-bath ultra-sonic dispersion, get micelle solution, get micelle solution, add lipophilic drugs or its solution, it is ultrasonic to pop one's head in, get hydrophobic modified chitin medicine carrying micelle, get the medicine carrying micelle solution, add bi-functional organic molecule solution, the mol ratio of control hydrophobic modified chitin and bi-functional organic molecule is 1: 1～100,15～50 ℃ of lower magnetic forces stirred 2～24 hours, got surface-modified hydrophobically modified oligochitosan medicine carrying micelle.
5. the preparation method of surface-modified hydrophobically modified oligochitosan medicine carrying micelle according to claim 4 is characterized in that: it is that 1～50kDa prepares hydrophobic modified chitin that the described oligochitosan aqueous solution of step (1) is selected molecular weight for use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100516010A CN100417417C (en) | 2006-05-24 | 2006-05-24 | Surface-modified hydrophobically modified drug-carried chitosan polymer micelle and method for preparing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100516010A CN100417417C (en) | 2006-05-24 | 2006-05-24 | Surface-modified hydrophobically modified drug-carried chitosan polymer micelle and method for preparing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1883708A CN1883708A (en) | 2006-12-27 |
| CN100417417C true CN100417417C (en) | 2008-09-10 |
Family
ID=37582092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100516010A Expired - Fee Related CN100417417C (en) | 2006-05-24 | 2006-05-24 | Surface-modified hydrophobically modified drug-carried chitosan polymer micelle and method for preparing same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100417417C (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011579B (en) * | 2006-12-29 | 2010-09-08 | 浙江大学 | Application of cytoplasm-targeting chitosan oligosaccharide-aliphatic acid grafting medicinal-vector colloidal cluster |
| CN101066458B (en) * | 2007-05-31 | 2010-05-26 | 浙江大学 | Application of cell nucleus targeting administration system capable of reversing tumor cell resistance |
| CN101148483B (en) * | 2007-11-08 | 2010-04-07 | 浙江大学 | Chitosan oligosaccharide-stearic acid grafting compound modified by folic acid, preparation method and application thereof |
| CN101293933B (en) * | 2008-06-17 | 2011-05-04 | 浙江大学 | Polyglycol modified chitosan oligosaccharide fatty acid grafting article, preparing method and application thereof |
| CN101711873B (en) * | 2008-10-06 | 2012-06-27 | 中国科学院大连化学物理研究所 | Method for preparing amphiphilic chitosan nanometer medicament carrier |
| CN101797220B (en) * | 2010-04-06 | 2011-12-07 | 浙江大学 | Oxaliplatin chitosan-stearic acid grafting micelle and application |
| CN101864078B (en) * | 2010-06-01 | 2011-12-07 | 浙江大学 | Polyethyleneimine-chitosan-octadecanoic acid grafting, preparation and application |
| RU2012154290A (en) * | 2010-06-16 | 2014-07-27 | Тропикана Продактс, Инк. | ENCAPSULATED SALTS AND THEIR APPLICATION IN DRINKS WITH HIGH ACIDITY |
| CN105920612A (en) * | 2016-06-12 | 2016-09-07 | 浙江大学 | Glucosamine-behenic acid grafting substance and preparation method |
| CN107115531A (en) * | 2017-05-05 | 2017-09-01 | 浙江大学 | A kind of glycolipid polymers modification nano structured lipid carrier and preparation method and application |
| CN107674210B (en) * | 2017-09-21 | 2020-09-29 | 浙江大学 | Triphenylphosphine-chitosan stearic acid graft drug-loaded micelle, preparation and application thereof |
| CN107778378A (en) * | 2017-10-26 | 2018-03-09 | 浙江大学 | Mannose-modified chitosan stearic acid grafting and preparation and application |
| CN108329404B (en) * | 2018-03-15 | 2020-08-04 | 浙江大学 | IR-780 iodide-chitosan stearic acid graft and preparation and application thereof |
| CN109394692B (en) * | 2018-12-12 | 2020-09-25 | 中国药科大学 | Dasatinib grafted polymer micelle, freeze-dried powder injection thereof, preparation method and application |
-
2006
- 2006-05-24 CN CNB2006100516010A patent/CN100417417C/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 壳寡糖嫁接硬脂酸阳离子聚合物胶团的制备及其理化性质. 叶轶青等.药学学报，第39卷第6期. 2004 |
| 壳寡糖嫁接硬脂酸阳离子聚合物胶团的制备及其理化性质. 叶轶青等.药学学报，第39卷第6期. 2004 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1883708A (en) | 2006-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100417417C (en) | Surface-modified hydrophobically modified drug-carried chitosan polymer micelle and method for preparing same | |
| Abdelhamid | Zeolitic imidazolate frameworks (ZIF-8) for biomedical applications: a review | |
| Barclay et al. | Review of polysaccharide particle-based functional drug delivery | |
| Peniche et al. | Chitosan nanoparticles: a contribution to nanomedicine | |
| Yang et al. | Redox-sensitive self-assembled nanoparticles based on alpha-tocopherol succinate-modified heparin for intracellular delivery of paclitaxel | |
| Gholamali et al. | Bio-nanocomposite polymer hydrogels containing nanoparticles for drug delivery: a review | |
| Prabaharan et al. | Chitosan-based particles as controlled drug delivery systems | |
| Kang et al. | Tailoring the stealth properties of biocompatible polysaccharide nanocontainers | |
| Ichikawa et al. | Formation of biocompatible nanoparticles by self-assembly of enzymatic hydrolysates of chitosan and carboxymethyl cellulose | |
| Su et al. | Synthesis and characterization of Schiff base contained dextran microgels in water-in-oil inverse microemulsion | |
| Ebara | Biomaterials nanoarchitectonics | |
| Chen et al. | pH-Sensitive drug delivery system based on modified dextrin coated mesoporous silica nanoparticles | |
| Zhang et al. | Self-assembled micelles based on Chondroitin sulfate/poly (d, l-lactideco-glycolide) block copolymers for doxorubicin delivery | |
| Han et al. | Functionalization and optimization-strategy of graphene oxide-based nanomaterials for gene and drug delivery | |
| CN101708162A (en) | Nanoparticle and preparation method thereof | |
| Chen et al. | Dual redox-triggered shell-sheddable micelles self-assembled from mPEGylated starch conjugates for rapid drug release | |
| CN108014344A (en) | PH and the chitosan nano pharmaceutical carrier and preparation method of temperature-responsive and application | |
| Huang et al. | Design and application of dextran carrier | |
| CN111870579B (en) | Tumor-targeted nano micelle, preparation method and application of nano micelle as drug carrier | |
| Chatterjee et al. | Cationic starch: A functionalized polysaccharide based polymer for advancement of drug delivery and health care system-A review | |
| Zhu et al. | Design of disintegrable nanoassemblies to release multiple small-sized nanoparticles | |
| CN101850122B (en) | Cholesterylchitosan nano carrier as well as medicament-carried nano particle and preparation method thereof | |
| Bera et al. | Etherified pullulan-polyethylenimine based nanoscaffolds improved chemosensitivity of erlotinib on hypoxic cancer cells. | |
| Ahmad et al. | Chitosan-based bionanocomposites in drug delivery | |
| Moscovici1 et al. | Nanocellulose and nanogels as modern drug delivery systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080910 Termination date: 20150524 |
|
| EXPY | Termination of patent right or utility model |